Welcome to our dedicated page for Ncs Multistage Hldgs SEC filings (Ticker: NCSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating sleeve sales data, frac-isolation backlog, or water-usage liabilities inside NCS Multistage’s dense disclosures can feel like hunting for a perforation in a 20-stage well. The company’s reports are rich with technical terms—pinpoint stimulation, coiled-tubing fracturing, stage isolation—that make traditional SEC research slow and error-prone.
Stock Titan solves this problem. Our AI reads every NCS Multistage SEC filing the moment it posts to EDGAR, then delivers plain-English answers investors actually search for: “NCS Multistage insider trading Form 4 transactions,” “NCS Multistage quarterly earnings report 10-Q filing,” and “understanding NCS Multistage SEC documents with AI.” Whether you need the latest 8-K material events explained or a NCS Multistage annual report 10-K simplified, one click opens an AI summary, key metrics table, and contextual risk flags.
All forms are covered in real time: 10-Ks for environmental obligations and impairment tests, 10-Qs for sleeve-installation revenue swings, 8-Ks for contract awards, and Form 4 insider data that highlight NCS Multistage executive stock transactions Form 4 during commodity up-cycles. Our platform also surfaces proxy statement compensation details and provides an NCS Multistage earnings report filing analysis that links cash-flow trends to North American rig counts. Stop scrolling through hundreds of pages; with Stock Titan you get NCS Multistage SEC filings explained simply—precise, searchable, and ready when you are.
NCS Multistage Holdings, Inc. (NCSM) filed a Form S-8 to register 250,000 additional shares of common stock (par $0.01) for issuance under its Amended & Restated 2017 Equity Incentive Plan. After this filing, a maximum 876,626 shares may be issued under the plan, inclusive of shares previously registered on four prior S-8 statements (2017, June 2020, December 2020, August 2023). All figures reflect the company’s 1-for-20 reverse stock split effective 1 Dec 2020.
The company is a non-accelerated filer and a smaller reporting company. Standard DGCL-based indemnification provisions, director exculpation (for directors only), and D&O insurance remain in place. Exhibits include the plan document (4.4), legal opinion (5.1), auditor consent (23.1) and filing-fee tables (107).
The registration enables NCSM to issue equity compensation without new capital inflow, potentially causing modest dilution but supporting employee retention and alignment.
NCSM’s Q2-25 10-Q shows a clear YoY turnaround. Revenue rose 23% to $36.5 mm, driven by a 46% jump in product sales that offset an 19% decline in service revenue. Consolidated gross profit improved $2.5 mm and the operating loss narrowed to $2.0 mm from $4.2 mm. A $1.0 mm deferred-tax benefit plus FX gains lifted net income attributable to NCS to $0.9 mm ($0.34 diluted EPS) versus a $3.1 mm loss (-$1.21) last year.
For the six months, revenue climbed 18% to $86.5 mm and net income swung to $5.0 mm ($1.84 diluted EPS). Canada contributed 49% of Q2 sales, the U.S. 37%, and other markets 14%.
Balance sheet. Cash remained healthy at $25.4 mm; NCS drew no amounts on its $35 mm ABL facility. Total debt consists solely of $7.7 mm of finance leases. Equity increased to $124.0 mm.
Cash flow. H1 operating cash inflow fell to $1.9 mm from $4.1 mm on higher working-capital needs; capex was modest at $0.7 mm.
Strategic update. On 31-Jul-25 NCS closed the $5.9 mm cash acquisition of Reservoir Metrics to expand tracer diagnostics, with an earn-out of up to $1.3 mm.
Risks & Outlook. Management cites stable Canadian activity, softer U.S. completions, potential international growth, and cost headwinds from steel/chemical tariffs. Ongoing Canadian patent appeals and U.S. litigation could affect future results but no gain/loss has been booked.